Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol
Introduction Type 2 diabetes mellitus (T2DM) is a highly heterogeneous and complex metabolic disease harbouring different metabolic characteristics. Adequate characterisation of subjects is essential to allow the implementation of precision medicine for the prevention, diagnosis, prognosis and treat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/12/e083825.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850250348769312768 |
|---|---|
| author | Marta Hernandez Josep Franch-Nadal Didac Mauricio Minerva Granado-Casas Àngels Molló Paula Garcia Francesc Xavier Cos Claramunt Bogdan Vlacho Berta Fernandez-Camins Albert Canudas Marta Ortega Alexandre Perera-LLuna Alejandro Boluda-Sanson Yesmina El-Khattabi-Ofkir Idoia Genua Trullos Inka Miñambres Natalia Riera Antonia Valsera Robles M Eulalia Pradas Sala Norma Ballestar Palacios Olga Vazquez Soler Cristina Ledesma Serrano Ana Cámara Caño Teresa Villuendas Begona Ribas Lopez Ana Maria Pedro Pijoan Eva Gonzalez Platas Eva Garcia Raquel Martí Eva Serra Llavall Montserrat Torra Solé Maite Puig Solé Ana Isabel Areny Tallaví Marc Olivart Neus Miro Vallve Marta Puig Fito Jesús Pujol Salud Cristina Garcia Serrano Eva Miquel Fernàndez Lidia Aran Sole Antonieta Lafarga Cristina Dominguez Amador Sandra Guerrero Cristina Farras Salles Maria Boldú Franque Lorena Arnay Mireia Marin Laura Turo Pere Anna Maria Torné Cortés Laia Llubes Arrià Cecilia Bañeres Argiles Assumpció Florensa Flix Manuel Mata Cases Carla Muñoz Isabel Bobe Elena Hernández Boluda María Begoña Cañas Diaz Xavier Peligros Palma Francisco Cegri Lombando Anna Martinez Sanchez Gabriel Cuatrecasas Anna Amorós Blanca Simon Anna Massana Raurich Maria Isabel Prieto Fernández Maria Olga Alvarez Fernández Robert Cabanes Gómez Ascensión Niubo Lopez Marta Crespo Boixasa Assumpció Altaba Barcelo Estel Felez Carroba Carme Olius Peyrats Eva Marsol Prieto Eva Ferris Gallart Maria Lluïsa Calonge Carbonell Roser Ros Barnadas Elena Artal Traveria Zulema Martí Oltra Carolina Lapena Estella Olga Poveda Jovellar Ana Carrera Rodriguez Sonia Aldea Gomez Xavier Herraiz Fabregat Elisabet Llop Lozano Ignacio Alborch Simó Laura Güell Espigol Pilar Pedro Benages Javier Parramon Nuñez Paloma Prats Berta Tió Carlos Arias Pelayo Martinez Cristian Llacer Pinos Roser Ferrer Costa Luz Maria Cruz Carlo |
| author_facet | Marta Hernandez Josep Franch-Nadal Didac Mauricio Minerva Granado-Casas Àngels Molló Paula Garcia Francesc Xavier Cos Claramunt Bogdan Vlacho Berta Fernandez-Camins Albert Canudas Marta Ortega Alexandre Perera-LLuna Alejandro Boluda-Sanson Yesmina El-Khattabi-Ofkir Idoia Genua Trullos Inka Miñambres Natalia Riera Antonia Valsera Robles M Eulalia Pradas Sala Norma Ballestar Palacios Olga Vazquez Soler Cristina Ledesma Serrano Ana Cámara Caño Teresa Villuendas Begona Ribas Lopez Ana Maria Pedro Pijoan Eva Gonzalez Platas Eva Garcia Raquel Martí Eva Serra Llavall Montserrat Torra Solé Maite Puig Solé Ana Isabel Areny Tallaví Marc Olivart Neus Miro Vallve Marta Puig Fito Jesús Pujol Salud Cristina Garcia Serrano Eva Miquel Fernàndez Lidia Aran Sole Antonieta Lafarga Cristina Dominguez Amador Sandra Guerrero Cristina Farras Salles Maria Boldú Franque Lorena Arnay Mireia Marin Laura Turo Pere Anna Maria Torné Cortés Laia Llubes Arrià Cecilia Bañeres Argiles Assumpció Florensa Flix Manuel Mata Cases Carla Muñoz Isabel Bobe Elena Hernández Boluda María Begoña Cañas Diaz Xavier Peligros Palma Francisco Cegri Lombando Anna Martinez Sanchez Gabriel Cuatrecasas Anna Amorós Blanca Simon Anna Massana Raurich Maria Isabel Prieto Fernández Maria Olga Alvarez Fernández Robert Cabanes Gómez Ascensión Niubo Lopez Marta Crespo Boixasa Assumpció Altaba Barcelo Estel Felez Carroba Carme Olius Peyrats Eva Marsol Prieto Eva Ferris Gallart Maria Lluïsa Calonge Carbonell Roser Ros Barnadas Elena Artal Traveria Zulema Martí Oltra Carolina Lapena Estella Olga Poveda Jovellar Ana Carrera Rodriguez Sonia Aldea Gomez Xavier Herraiz Fabregat Elisabet Llop Lozano Ignacio Alborch Simó Laura Güell Espigol Pilar Pedro Benages Javier Parramon Nuñez Paloma Prats Berta Tió Carlos Arias Pelayo Martinez Cristian Llacer Pinos Roser Ferrer Costa Luz Maria Cruz Carlo |
| collection | DOAJ |
| description | Introduction Type 2 diabetes mellitus (T2DM) is a highly heterogeneous and complex metabolic disease harbouring different metabolic characteristics. Adequate characterisation of subjects is essential to allow the implementation of precision medicine for the prevention, diagnosis, prognosis and treatment of this condition.Methods and analysis This prospective observational cohort study aims to identify and characterise relevant clinical clusters that are reproducibly associated with various clinical outcomes in T2DM in our Mediterranean region. The COPERNICAN study will include 1200 subjects with newly diagnosed T2DM from 28 primary care centres from the city of Barcelona and the healthcare district of Lleida in Catalonia (Spain). Participants will undergo a comprehensive phenotypic evaluation including, among others, six relevant variables: age, antibodies against glutamic acid decarboxylase, body mass index, glycated haemoglobin (HbA1c), indexes of insulin sensibility (HOMA2-IR) and secretion (HOMA2-beta). We will collect additional comprehensive data on glucose-lowering and other drug treatments, clinical evaluation (including complications), laboratory parameters, advanced lipoprotein profile, dietary habits and physical activity. The linkage with the population database will be done to perform a pragmatic follow-up of participants as part of their usual clinical care. A state-of-the-art cluster analysis (k-means and hierarchical clustering) will be performed.Ethics and dissemination The present study complies with all the ethical aspects and protection of participant subjects complying with all current local and European Union legislation. All Ethics Committees from the institutions involved in the study (IR Sant Pau Ethics Committee, Ethics Committee for Drug Research at IDIAP Jordi Gol and University Hospital of Bellvitge Ethics Committee for Research) approved this protocol. Confidentiality and anonymity of the data are ensured according to the current Spanish Organic Law 3/2018 of 05 December.Trial registration number ClinicalTrials.gov. registration number NCT05333718, 27 January 2023. |
| format | Article |
| id | doaj-art-8dedf19d0c034b3dad6aba731a0de633 |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-8dedf19d0c034b3dad6aba731a0de6332025-08-20T01:58:12ZengBMJ Publishing GroupBMJ Open2044-60552024-12-01141210.1136/bmjopen-2023-083825Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol 0Marta HernandezJosep Franch-Nadal1Didac Mauricio2Minerva Granado-Casas3Àngels MollóPaula GarciaFrancesc Xavier Cos ClaramuntBogdan Vlacho4Berta Fernandez-Camins5Albert Canudas6Marta Ortega7Alexandre Perera-LLuna8Alejandro Boluda-Sanson9Yesmina El-Khattabi-Ofkir10Idoia Genua TrullosInka MiñambresNatalia RieraAntonia Valsera RoblesM Eulalia Pradas SalaNorma Ballestar PalaciosOlga Vazquez SolerCristina Ledesma SerranoAna Cámara CañoTeresa VilluendasBegona Ribas LopezAna Maria Pedro PijoanEva Gonzalez PlatasEva GarciaRaquel MartíEva Serra LlavallMontserrat Torra SoléMaite Puig SoléAna Isabel Areny TallavíMarc OlivartNeus Miro VallveMarta Puig FitoJesús Pujol SaludCristina Garcia SerranoEva Miquel FernàndezLidia Aran SoleAntonieta LafargaCristina Dominguez AmadorSandra GuerreroCristina Farras SallesMaria Boldú FranqueLorena ArnayMireia MarinLaura Turo PereAnna Maria Torné CortésLaia Llubes ArriàCecilia Bañeres ArgilesAssumpció Florensa FlixManuel Mata CasesCarla MuñozIsabel BobeElena Hernández BoludaMaría Begoña Cañas DiazXavier Peligros PalmaFrancisco Cegri LombandoAnna Martinez SanchezGabriel CuatrecasasAnna AmorósBlanca SimonAnna Massana RaurichMaria Isabel Prieto FernándezMaria Olga Alvarez FernándezRobert Cabanes GómezAscensión Niubo LopezMarta Crespo BoixasaAssumpció Altaba BarceloEstel Felez CarrobaCarme Olius PeyratsEva Marsol PrietoEva Ferris GallartMaria Lluïsa Calonge CarbonellRoser Ros BarnadasElena Artal TraveriaZulema Martí OltraCarolina Lapena EstellaOlga Poveda JovellarAna Carrera RodriguezSonia Aldea GomezXavier Herraiz FabregatElisabet Llop LozanoIgnacio Alborch SimóLaura Güell EspigolPilar Pedro BenagesJavier Parramon NuñezPaloma PratsBerta TióCarlos AriasPelayo MartinezCristian Llacer PinosRoser Ferrer CostaLuz Maria Cruz CarloNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA2 Department of Medicine, University of Barcelona, Barcelona, Spain1 Department of Endocrinology and Nutrition, IR Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain3 DAP_CAT group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol, IDIAP Jordi Gol, Barcelona, Spain3 DAP_CAT group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol, IDIAP Jordi Gol, Barcelona, Spain1 Department of Endocrinology and Nutrition, IR Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain5 Escola de Doctorat. Departament de Medicina, Infermeria i ciències de la Salut, University of Lleida, Lleida, Spain6 Fundació Institut Universitari per a la recerca a l`Atenció Primària de Salut Jordi Gol i Gurina, IDIAP Jordi Gol, Barcelona, Spain9 Networking Biomedical Research Centre in the subject area of Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid, Spain1 Department of Endocrinology and Nutrition, IR Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain8 Health Care Research Group (GRECS), Lleida Institute of Biomedical Research Foundation Dr Pifarré, Lleida, SpainIntroduction Type 2 diabetes mellitus (T2DM) is a highly heterogeneous and complex metabolic disease harbouring different metabolic characteristics. Adequate characterisation of subjects is essential to allow the implementation of precision medicine for the prevention, diagnosis, prognosis and treatment of this condition.Methods and analysis This prospective observational cohort study aims to identify and characterise relevant clinical clusters that are reproducibly associated with various clinical outcomes in T2DM in our Mediterranean region. The COPERNICAN study will include 1200 subjects with newly diagnosed T2DM from 28 primary care centres from the city of Barcelona and the healthcare district of Lleida in Catalonia (Spain). Participants will undergo a comprehensive phenotypic evaluation including, among others, six relevant variables: age, antibodies against glutamic acid decarboxylase, body mass index, glycated haemoglobin (HbA1c), indexes of insulin sensibility (HOMA2-IR) and secretion (HOMA2-beta). We will collect additional comprehensive data on glucose-lowering and other drug treatments, clinical evaluation (including complications), laboratory parameters, advanced lipoprotein profile, dietary habits and physical activity. The linkage with the population database will be done to perform a pragmatic follow-up of participants as part of their usual clinical care. A state-of-the-art cluster analysis (k-means and hierarchical clustering) will be performed.Ethics and dissemination The present study complies with all the ethical aspects and protection of participant subjects complying with all current local and European Union legislation. All Ethics Committees from the institutions involved in the study (IR Sant Pau Ethics Committee, Ethics Committee for Drug Research at IDIAP Jordi Gol and University Hospital of Bellvitge Ethics Committee for Research) approved this protocol. Confidentiality and anonymity of the data are ensured according to the current Spanish Organic Law 3/2018 of 05 December.Trial registration number ClinicalTrials.gov. registration number NCT05333718, 27 January 2023.https://bmjopen.bmj.com/content/14/12/e083825.full |
| spellingShingle | Marta Hernandez Josep Franch-Nadal Didac Mauricio Minerva Granado-Casas Àngels Molló Paula Garcia Francesc Xavier Cos Claramunt Bogdan Vlacho Berta Fernandez-Camins Albert Canudas Marta Ortega Alexandre Perera-LLuna Alejandro Boluda-Sanson Yesmina El-Khattabi-Ofkir Idoia Genua Trullos Inka Miñambres Natalia Riera Antonia Valsera Robles M Eulalia Pradas Sala Norma Ballestar Palacios Olga Vazquez Soler Cristina Ledesma Serrano Ana Cámara Caño Teresa Villuendas Begona Ribas Lopez Ana Maria Pedro Pijoan Eva Gonzalez Platas Eva Garcia Raquel Martí Eva Serra Llavall Montserrat Torra Solé Maite Puig Solé Ana Isabel Areny Tallaví Marc Olivart Neus Miro Vallve Marta Puig Fito Jesús Pujol Salud Cristina Garcia Serrano Eva Miquel Fernàndez Lidia Aran Sole Antonieta Lafarga Cristina Dominguez Amador Sandra Guerrero Cristina Farras Salles Maria Boldú Franque Lorena Arnay Mireia Marin Laura Turo Pere Anna Maria Torné Cortés Laia Llubes Arrià Cecilia Bañeres Argiles Assumpció Florensa Flix Manuel Mata Cases Carla Muñoz Isabel Bobe Elena Hernández Boluda María Begoña Cañas Diaz Xavier Peligros Palma Francisco Cegri Lombando Anna Martinez Sanchez Gabriel Cuatrecasas Anna Amorós Blanca Simon Anna Massana Raurich Maria Isabel Prieto Fernández Maria Olga Alvarez Fernández Robert Cabanes Gómez Ascensión Niubo Lopez Marta Crespo Boixasa Assumpció Altaba Barcelo Estel Felez Carroba Carme Olius Peyrats Eva Marsol Prieto Eva Ferris Gallart Maria Lluïsa Calonge Carbonell Roser Ros Barnadas Elena Artal Traveria Zulema Martí Oltra Carolina Lapena Estella Olga Poveda Jovellar Ana Carrera Rodriguez Sonia Aldea Gomez Xavier Herraiz Fabregat Elisabet Llop Lozano Ignacio Alborch Simó Laura Güell Espigol Pilar Pedro Benages Javier Parramon Nuñez Paloma Prats Berta Tió Carlos Arias Pelayo Martinez Cristian Llacer Pinos Roser Ferrer Costa Luz Maria Cruz Carlo Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol BMJ Open |
| title | Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol |
| title_full | Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol |
| title_fullStr | Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol |
| title_full_unstemmed | Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol |
| title_short | Characterisation of type 2 diabetes subgroups at diagnosis: the COPERNICAN prospective observational cohort study protocol |
| title_sort | characterisation of type 2 diabetes subgroups at diagnosis the copernican prospective observational cohort study protocol |
| url | https://bmjopen.bmj.com/content/14/12/e083825.full |
| work_keys_str_mv | AT characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT martahernandez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT josepfranchnadal characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT didacmauricio characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT minervagranadocasas characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT angelsmollo characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT paulagarcia characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT francescxaviercosclaramunt characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT bogdanvlacho characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT bertafernandezcamins characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT albertcanudas characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT martaortega characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT alexandrepereralluna characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT alejandroboludasanson characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT yesminaelkhattabiofkir characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT idoiagenuatrullos characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT inkaminambres characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT nataliariera characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT antoniavalserarobles characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT meulaliapradassala characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT normaballestarpalacios characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT olgavazquezsoler characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT cristinaledesmaserrano characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT anacamaracano characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT teresavilluendas characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT begonaribaslopez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT anamariapedropijoan characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT evagonzalezplatas characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT evagarcia characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT raquelmarti characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT evaserrallavall characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT montserrattorrasole characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT maitepuigsole characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT anaisabelarenytallavi characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT marcolivart characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT neusmirovallve characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT martapuigfito characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT jesuspujolsalud characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT cristinagarciaserrano characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT evamiquelfernandez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT lidiaaransole characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT antonietalafarga characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT cristinadominguezamador characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT sandraguerrero characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT cristinafarrassalles characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT mariaboldufranque characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT lorenaarnay characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT mireiamarin characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT lauraturopere characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT annamariatornecortes characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT laiallubesarria characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT ceciliabaneresargiles characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT assumpcioflorensaflix characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT manuelmatacases characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT carlamunoz characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT isabelbobe characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT elenahernandezboluda characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT mariabegonacanasdiaz characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT xavierpeligrospalma characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT franciscocegrilombando characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT annamartinezsanchez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT gabrielcuatrecasas characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT annaamoros characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT blancasimon characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT annamassanaraurich characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT mariaisabelprietofernandez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT mariaolgaalvarezfernandez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT robertcabanesgomez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT ascensionniubolopez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT martacrespoboixasa characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT assumpcioaltababarcelo characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT estelfelezcarroba characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT carmeoliuspeyrats characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT evamarsolprieto characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT evaferrisgallart characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT marialluisacalongecarbonell characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT roserrosbarnadas characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT elenaartaltraveria characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT zulemamartioltra characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT carolinalapenaestella characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT olgapovedajovellar characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT anacarrerarodriguez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT soniaaldeagomez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT xavierherraizfabregat characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT elisabetlloplozano characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT ignacioalborchsimo characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT lauraguellespigol characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT pilarpedrobenages characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT javierparramonnunez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT palomaprats characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT bertatio characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT carlosarias characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT pelayomartinez characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT cristianllacerpinos characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT roserferrercosta characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol AT luzmariacruzcarlo characterisationoftype2diabetessubgroupsatdiagnosisthecopernicanprospectiveobservationalcohortstudyprotocol |